Immunogenicity and Safety of Inactivated H1N1 Swine-origin Influenza Monovalent Vaccine in Immunocompromised Children and Young Adults
This is a prospective observational study. This study will not dictate vaccine
administration, nor the vaccine product to be used. It will collect data in St Jude patients
who will receive the vaccine as part of their clinical care per institutional guidelines.
Research participants will receive two doses of inactivated H1N1 swine-origin monovalent
influenza vaccine administered 28 days apart as part of clinical care. Each dose contains
15 mcg of hemagglutinin antigen (HA).Follow-up visits will be scheduled 28 days after each
dose and at day 208+/- 14 days for blood work. The day of administration of the first
vaccine dose is counted as day 0. At each of these visits, blood will be collected to assess
for immunogenicity. Research participants will be given a diary card to record symptoms for
28 days . They will be asked to bring this diary back at the next visit. Other
vaccine-related adverse events will also be collected by retrospective chart review.
Children and young adults between the ages of 6 months and 21 years and 13 kg or greater in
body weight who have an underlying diagnosis of cancer, HIV, sickle cell disease or receipt
of a stem cell transplant more than a year prior to study entry and who will receive
inactivated H1N1 swine-origin monovalent influenza vaccine in the winter/fall of 2009-2010
as part of their routine clinical care.
Observational Model: Case-Only, Time Perspective: Prospective
This study will document Seroprotection (a post-vaccine antibody response ≥ an HI titer of 1:40).
Hana Hakim, MD
St. Jude Children's Research Hospital
United States: Institutional Review Board
|St.Jude Children's Research Hospital||Memphis, Tennessee 38105|